Every "best peptides" list we could find ranks products. This one ranks the evidence, because that is the part a reader cannot check for themselves in an afternoon. On 2026-09-06 we counted the randomized controlled trials indexed on PubMed for each peptide sold into skincare, read what each trial actually tested, and noted who paid for it. The order below follows that count. It is not a product ranking, and nothing here is scored or affiliate-linked.
The ranking
| Rank | Ingredient | Randomized trials indexed | What the best trial showed | Who funded it |
|---|---|---|---|---|
| 1 | Oral collagen peptides | 38 | Improved hydration and elasticity vs placebo across two meta-analyses (1,125 and 1,721 participants) | Mostly the collagen's makers |
| 2 | Acetyl hexapeptide-8 (Argireline) | 2 (1 cosmetic) | Reduced wrinkles vs placebo, Chinese subjects, 2013 | Not stated as independent |
| 3 | Cyclized hexapeptide-9 | 1 | Beat 0.002% retinol on crow's feet and forehead wrinkles over 56 days | Its developer |
| 4 | Palmitoyl pentapeptide-4 (Matrixyl) | 1 (not a wrinkle trial) | A radiotherapy skin-care comparison, 2004; wrinkle evidence is supplier material | Supplier |
| 5 | Copper tripeptide (GHK-Cu) | 1 | No objective benefit in 13 laser patients; a separate sponsor-funded trial reported 24.1% vs 15.0% | The serum's maker |
| 6 | Acetyl octapeptide-3 (SNAP-8) | 0 | Nothing published; the supplier's 17-woman test reports a maximum, not a mean | Supplier |
| — | Benchmark: retinoids | 55 | Decades of photoaging trials | Mixed, including public funding |
Why collagen ranks first, and why that is awkward
The largest body of human evidence attached to the word "peptide" in beauty belongs to something you drink. Two meta-analyses of randomized placebo-controlled trials — 19 trials with 1,125 participants (de Miranda et al., Int J Dermatol 2021) and 26 trials with 1,721 (Pu et al., Nutrients 2023) — found improvements in skin hydration and elasticity against placebo. The 2023 review flagged several biases in the trials it pooled, and most were funded by collagen manufacturers.
The awkward part is that this evidence transfers to nothing else on the list. An oral collagen peptide is digested to amino acids and short fragments and reaches skin through the blood; a topical signal peptide is a different molecule taking a different route at parts-per-million concentrations. Marketing moves the credibility across that gap routinely. Our collagen page separates the two.
Second: Argireline, the one single-peptide cosmetic trial
Acetyl hexapeptide-8 has 22 human PubMed records and two typed as randomized controlled trials, of which one is a cosmetic wrinkle study in Chinese subjects and the other treats blepharospasm in patients already receiving botulinum toxin. That single cosmetic trial is more than any other named topical peptide has.
It also sits against the clearest penetration problem in the category. The FDA's own study found 0.22% of a 10% dose remaining in the stratum corneum and 0.01% reaching the epidermis after 24 hours, and the Cosmetic Ingredient Review panel assessed the ingredient as safe up to 0.005% with data insufficient above that — while products advertise 10%, two thousand times higher. Full detail on our Argireline page.
Third: the peptide that beat retinol, from the company that makes it
The most striking recent result in this field is a randomized, double-blinded, active- and vehicle-controlled trial of a cyclized hexapeptide-9. Volunteers used 0.002% CHP-9 serum, 0.002% retinol serum, or vehicle, twice daily for 56 days. The peptide significantly reduced the number, area and roughness of both crow's feet and forehead wrinkles; retinol at the same concentration moved fewer endpoints, and the peptide's effect was significantly larger on all but one (Chang et al., J Cosmet Dermatol 2025).
It is a well-designed trial with an active comparator, which is rare here. Every author works at the Global R&D Center of Shanghai Chicmax Cosmetic Co. or Shanghai Kans Biotech, which develop and sell the peptide; the paper declares no conflicts. Nobody outside those companies has replicated it. That is why it ranks third rather than first despite being the strongest single result on the page.
Fourth and fifth: Matrixyl and copper, the two most-marketed
Palmitoyl pentapeptide-4 has one PubMed record typed as a randomized trial, and it compared a cream against Bepanthol lotion in breast-cancer patients undergoing radiotherapy (Strahlenther Onkol 2004) — not a wrinkle study. Its wrinkle evidence is supplier documentation and studies of multi-ingredient products. At about 578 Da it is also above the 500-dalton threshold for passive skin penetration.
Copper tripeptide is the most-written-about ingredient in beauty peptides and has one indexed randomized trial: 13 patients after CO2 laser resurfacing, randomized to a regimen with or without GHK-Cu, in which blinded evaluators and image analysis found no significant difference in erythema, wrinkles or skin quality; only the patients' own satisfaction scores separated the groups (Miller et al., Arch Facial Plast Surg 2006). The positive 40-woman trial that consumer articles cite was funded by the serum's maker and is not indexed on PubMed. Both belong in the record; our copper peptides page carries all of it.
Last: the ingredient with nothing
Acetyl octapeptide-3 (SNAP-8) returned zero human records on PubMed — not zero trials, zero records of any kind. Its efficacy evidence is one supplier test on 17 women reporting a maximum wrinkle-depth reduction of 63%, with no mean, no control and no publication, on a datasheet whose own footer says it must not be presented as claim substantiation to a regulator. It is sold at premium prices. See SNAP-8.
What ranking by evidence cannot tell you
It cannot tell you what will work on your face. Small trials with instrument endpoints, run by the people selling the ingredient, over eight to twelve weeks, are what this category has; none of them predicts an individual result, and none was designed to. Tolerance is where peptides have a genuine, repeatedly measured advantage over retinoids — the 2010 comparison against 0.02% tretinoin found the peptide-containing cosmetic regimen significantly better tolerated by every measure at 8 weeks. And the ranking says nothing about formulation, which for a molecule that struggles to cross the stratum corneum may matter more than which peptide is in the bottle.
We do not rank products here. When our own testing programme has run its six-week protocol, product pages will say what was tested, for how long, and by whom. Until then, an evidence count is the honest version of "best".
Next: the whole category counted and explained, the ingredient pages, and if you are considering the injectable end, the glow stack.
Sources
- PubMed census run 2026-09-06 via NCBI E-utilities; search strings printed on peptides for skin. PubMed.
- Chang H, et al. Novel Cyclized Hexapeptide-9 Outperforms Retinol Against Skin Aging. J Cosmet Dermatol 2025;24(7):e70290. PubMed 40586182.
- Miller TR, et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006;8(4):252-9. PubMed 16847171.
- Wang Y, et al. The anti-wrinkle efficacy of argireline in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol 2013;14(2):147-53. PubMed 23417317.
- Fu JJ, et al. Cosmetic niacinamide/peptide/retinyl propionate regimen vs. 0.02% tretinoin. Br J Dermatol 2010;162(3):647-54. PubMed 20374604.
- Röper B, et al. Thêta-Cream versus Bepanthol lotion in breast cancer patients under radiotherapy. Strahlenther Onkol 2004;180(5):315-22. PubMed 15127162.
- de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol 2021;60(12):1449-61. PubMed 33742704.
- Pu SY, Huang YL, Pu CM, et al. Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis. Nutrients 2023;15(9). PubMed 37432180.
- Penetration, CIR and supplier-datasheet figures as sourced on our Argireline, Matrixyl, SNAP-8 and copper peptides pages.
Published by Peptide Glow Journal Editorial. This page ranks published evidence for ingredients. No product, brand or vendor is ranked, scored or affiliate-linked.